Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

Ilkoo Noh; Hyun Ouk Kim; Jihye Choi; Yuna Choi; Dong Ki Lee; Yong Min Huh; Seungjoo Haam

doi:10.1016/j.biomaterials.2015.03.006

Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

Ilkoo Noh, Hyun Ouk Kim, Jihye Choi, Yuna Choi, Dong Ki Lee, Yong Min Huh, Seungjoo Haam

Research output: Contribution to journal › Article › peer-review

105 Citations (Scopus)

Abstract

Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An invitro study of cell viability and mRNA expression levels and an invivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.

Original language	English
Pages (from-to)	763-774
Number of pages	12
Journal	Biomaterials
Volume	53
DOIs	https://doi.org/10.1016/j.biomaterials.2015.03.006
Publication status	Published - 2015 Jun 1

Bibliographical note

Funding Information:
This work was supported by the Industrial Strategic Technology Development Program ( 10044021 , Development of nonvascular drug eluting stent for treatment of gastrointestinal disease) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) ( 2010-0019923 ).

Publisher Copyright:
© 2015 Elsevier Ltd.

All Science Journal Classification (ASJC) codes

Biophysics
Bioengineering
Ceramics and Composites
Biomaterials
Mechanics of Materials

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2015.03.006

Cite this

@article{fbb41efcb31048e4a8f09797d1f14f4d,

title = "Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer",

abstract = "Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An invitro study of cell viability and mRNA expression levels and an invivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.",

author = "Ilkoo Noh and Kim, {Hyun Ouk} and Jihye Choi and Yuna Choi and Lee, {Dong Ki} and Huh, {Yong Min} and Seungjoo Haam",

note = "Funding Information: This work was supported by the Industrial Strategic Technology Development Program ( 10044021 , Development of nonvascular drug eluting stent for treatment of gastrointestinal disease) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) ( 2010-0019923 ). Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.biomaterials.2015.03.006",

language = "English",

volume = "53",

pages = "763--774",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

AU - Noh, Ilkoo

AU - Kim, Hyun Ouk

AU - Choi, Jihye

AU - Choi, Yuna

AU - Lee, Dong Ki

AU - Huh, Yong Min

AU - Haam, Seungjoo

N1 - Funding Information: This work was supported by the Industrial Strategic Technology Development Program ( 10044021 , Development of nonvascular drug eluting stent for treatment of gastrointestinal disease) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) ( 2010-0019923 ). Publisher Copyright: © 2015 Elsevier Ltd.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An invitro study of cell viability and mRNA expression levels and an invivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.

AB - Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An invitro study of cell viability and mRNA expression levels and an invivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84927931045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927931045&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.03.006

DO - 10.1016/j.biomaterials.2015.03.006

M3 - Article

C2 - 25890771

AN - SCOPUS:84927931045

SN - 0142-9612

VL - 53

SP - 763

EP - 774

JO - Biomaterials

JF - Biomaterials

ER -

Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this